Express Mail No.: EV 871029106 US

Date of Deposit: November 13, 2008

Page 1 of 2

Attorney Docket No.: 21534-002 CIP NATL

NOV 1 3 2008 INFORMAT STATEMEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/540,635
Filing Date	December 12, 2005
First Named Inventor	Haines
Group Art Unit	4161
Examiner Name	Sean M. Basquill
Attorney Docket Number	21534-002 CIP NATL

	U.S. PATENT DOCUMENTS										
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate				
	*A1	4,879,312	11/07/89	Kamarei et al.	514	560					
	*A2	5,569,585	10/29/96	Goodwin et al.	435	6					
	*A3	6,103,756	08/15/00	Gorsek	514	458					

	U.S. PUBLISHED APPLICATION DOCUMENTS										
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate				
	*A4	2002/0002154 A1	01/03/02	Guivarc'h et al.	514	174					
	*A5	2002/0110604 A1	08/15/02	Babish, et al.	424	725					

	FOREIGN PATENT DOCUMENTS										
Exam Initials	Cite No.	Foreiq Office	Name of Patentee(s) of Applicant(s)		Date of Publication	Translat Yes	tion No				
	*B1	wo	01/85206 A2	Haines, et al.	11/15/01						
	*B2	JP	01-156923 A	Haines, et al.	06/20/90	Abstract only					

al sa		THER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C1	Baek, et al., "The Effects of Two New Antagonists of Secretory PLA ₂ on TNF, iNOS, and COX-2 Expression in Activated Macrophages", SHOCK, 12(6):473-478 (1999).
	*C2	Beauregard, et al., "Induction of Nitric Oxide Synthase and Over-Production of Nitric Oxide by Interleukin-1ß in Cultured Lacrimal Gland Acinar Cells", Exp. Eye Res., 77(1):109-114 (2003).
	*C3	Chen, et al., "A 3D-QSAR Study on Ginkgolides and Their Analogues with Comparative Molecular Field Analysis", Bioorg. Med. Chem. Lett., 8(11):1291-1296 (1998).
	*C4	Fan, et al., "Does Astaxanthin Protect Haematococcus Against Light Damage?", Z. Naturforsch., C53, pp. 93-100 (1998).
	*C5	Fies, et al., "Ginkgo Extract in Impaired Vision—Treatment with Special Extract EGb 761 of Impaired Vision Due to Dry Senile Macular Degeneration", Wien. Med. Wochenschr., 152(15/16):423-426 (2002).
	*C6	Guex-Crosier, "Non-Steroidal Anti-Inflammatory Drugs and Ocular Inflammation", Klin. Monatsbl. Augenheilkd., 218(5):305-308 (2001).
	*C7	Jyonouchi, et al., "Immunomodulating Actions of Carotenoids: Enhancement of In Vitro Antibody Production to T-Dependent Antigens", <i>Nutr. Cancer</i> , 21(1):47-58 (1994).
	*C8	Jyonouchi, et al., "Effects of Various Carotenoids on Cloned, Effector-Stage T-Helper Cell Activity", <i>Nutr. Cancer</i> , 26(3):313-324 (1996).
	*C9	Kurashige, et al., "Inhibition of Oxidative Injury of Biological Membranes by Astaxanthin", <i>Physiol. Chem. Phys. & Med. NMR</i> , 22(1):27-38 (1990).

Express Mail No.: EV 871029106 US Date of Deposit: November 13, 2008

Page 2 of 2 Attorney Docket No.: 21534-002 CIP NATL

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.						
	*C10	Li, et al., "The Bioavailability of Ginkgolides in Ginkgo Biloba Extracts", Planta Medica, 63(6):563-565 (1997).						
	*C11	Lobefalo, et al., "Dry Eye in Allergic Conjunctivitis: Role of Inflammatory Infiltrate", Int. J. Immunopathol. Pharmacol., 12(3):133-137 (1999).						
	*C12	Morrow, et al., "Increase in Circulating Products of Lipid Peroxidation (F ₂ -Isoprostanes) in Smokers", N.E.J. Med., 332:1198-1203 (1995).						
	*C13	Newsholme, et al., "Camp-Specific Phosphodiesterase Inhibitor, Rolipram, Reduces Eosinophil Infiltration Evoked by Leukotrienes or by Histamine in Guinea Pig Conjunctiva", <i>Inflammation</i> , 17(1):25-31 (1993).						
	*C14	Okai, et al., "Possible Immunomodulating Activities of Carotenoids in In Vitro Cell Culture Experiments", Int. J. Immunopharmac., 18(12):753-758 (1996).						
	*C15	Saponara, et al., "Inhibition of cAMP-Phosphodiesterase by Biflavones of Ginkgo Biloba in Rat Adipose Tissue", J. Nat. Prod., 61(11):1386-1387 (1998).						
	*C16	Shaban, et al., "Phosphatidylglycerol Potently Protects Human Retinal Pigment Epithelial Cells Against Apoptosis Induced by A2E, a Compound Suspected to Cause Age-Related Macula Degeneration", <i>Exp. Eye Res.</i> , 75(1):99-108 (2002).						
	*C17	Vint, et al., "The Gold Anti-Rheumatic Drug Auranofin Governs T Cell Activation by Enhancing Oxygen Free Radical Production", Eur. J. Immunol., 24(9):1961-1965 (1994).						
.,	*C18	Vint, et al., "The Interaction of Auranofin and Buthionine Sulfoximine Blocks Activation of Human Peripheral T Lymphocytes", Cell. Immunol., 152(1):152-161 (1993).						
·	*C19	Vint, et al., "The Effects of Auranofin on Activation and Interleukin-2 Release from Human Peripheral Blood Mononuclear Cells", Agents and Actions, 40(3/4):209-214 (1993).						
	*C20	Wang, et al., "Astaxanthin-Rich Algal Meal and Vitamin C Inhibit Helicobacter Pylori Infection in BALB/cA Mice", Antimicrobial Agents and Chemotherapy, 44(9):2452-2457 (2000).						

^{*} a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior applications, Serial No.10/621,802, filed July 16, 2003, and Serial No. 10/345,856, filed January 16, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications)

Examiner Signature	Date Considered	
-----------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4472559v.1

Express Mail No.: EV 871029106 US Date of Deposit: November 13, 2008

8 J VON

Page 1 of 2 Attorney Docket No.: 21534-002 CIP NATL

Modified	Form 14	49/PTO					Application Number	1:	0/540,6	35				
\$\			•				Filing Date	December 12, 2005						
(بىر 108	INFO	RMAT	TION DISC	LOS	JRE		First Named Inventor			Haines				
Æ/	STATEMENT BY APPLICANT				ANT		Group Art Unit	4	161					
					Examiner Name	S	ean M.	Basquil			_			
							Attorney Docket Number	2	1534-00	02 CIP N	NATL			
					1	Ü.S	S. PATENT DOCUMENTS			3.3			Š	
Exam nitials	Cite No.		Patent ment No.	Issu	e Date	1	e of Patentee(s) or Applicant(s)	Class Sub Filing Class If Appl			Date propriate)		
	*A1	4,879	,312	11/0	7/89	Kama	arei et al.	5	14	560				
	*A2	5,569	,585	10/2	9/96	Good	dwin et al.	4:	35	6			_	
_	*A3	6,103	,756	08/1	5/00	Gors	ek	5	14	458				
31494					" U.S	. PUBL	ISHED APPLICATION DOCUMENTS							
Exam nitials	Cite No.		.S. Publishoplication N		Publi Da	shed ite	Name of Patentee(s) or Applicant(s)		Class		5	Filing E If Appropr)a	
	*A4	2002	2/0002154	41	01/03	3/02	Guivarc'h et al.		514	174		Дрргорі		
	*A5		2/0110604 /	A1	08/15	6/02	Babish, et al.		424	725			_	
						FORE	IGN PATENT DOCUMENTS			, War				
xam nitials				of Patentee(s) or Applicant(s)		ite of iblicatio	n	Tran Yes	slation No	20000				
	*B1	wo	01/85206	A2		Haine	s, et al.	11/15/01					_	
	*B2	JP				Haine	s, et al.	06	/20/90		Abstra only	ct	_	

Exam	Cite	The state of the s
nitials	No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C1	Baek, et al., "The Effects of Two New Antagonists of Secretory PLA ₂ on TNF, iNOS, and COX-2 Expression in Activated Macrophages", SHOCK, 12(6):473-478 (1999).
	*C2	Beauregard, et al., "Induction of Nitric Oxide Synthase and Over-Production of Nitric Oxide by Interleukin-1ß in Cultured Lacrimal Gland Acinar Cells", Exp. Eye Res., 77(1):109-114 (2003).
	*C3	Chen, et al., "A 3D-QSAR Study on Ginkgolides and Their Analogues with Comparative Molecular Field Analysis". Bioorg. Med. Chem. Lett., 8(11):1291-1296 (1998).
	*C4	Fan, et al., "Does Astaxanthin Protect Haematococcus Against Light Damage?", Z. Naturforsch., C53, pp. 93-100 (1998).
	*C5	Fies, et al., "Ginkgo Extract in Impaired Vision—Treatment with Special Extract EGb 761 of Impaired Vision Due to Dry Senile Macular Degeneration", Wien. Med. Wochenschr., 152(15/16):423-426 (2002).
	*C6	Guex-Crosier, "Non-Steroidal Anti-Inflammatory Drugs and Ocular Inflammation", Klin. Monatsbl. Augenheilkd., 218(5):305-308 (2001).
	*C7	Jyonouchi, et al., "Immunomodulating Actions of Carotenoids: Enhancement of In Vitro Antibody Production to T-Dependent Antigens", <i>Nutr. Cancer</i> , 21(1):47-58 (1994).
	*C8	Jyonouchi, et al., "Effects of Various Carotenoids on Cloned, Effector-Stage T-Helper Cell Activity", <i>Nutr. Cancer</i> , 26(3):313-324 (1996).
	*C9	Kurashige, et al., "Inhibition of Oxidative Injury of Biological Membranes by Astaxanthin", <i>Physiol. Chem. Phys. & Med. NMR</i> , 22(1):27-38 (1990).

Express Mail No.: EV 871029106 US Date of Deposit: November 13, 2008

Page 2 of 2 Attorney Docket No.: 21534-002 CIP NATL

		THER PRIOR ART NON PATENTILITE RATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C10	Li, et al., "The Bioavailability of Ginkgolides in Ginkgo Biloba Extracts", Planta Medica, 63(6):563-565 (1997).
	*C11	Lobefalo, et al., "Dry Eye in Allergic Conjunctivitis: Role of Inflammatory Infiltrate", Int. J. Immunopathol. Pharmacol., 12(3):133-137 (1999).
	*C12	Morrow, et al., "Increase in Circulating Products of Lipid Peroxidation (F ₂ -Isoprostanes) in Smokers", <i>N.E.J. Med.</i> , 332:1198-1203 (1995).
	*C13	Newsholme, et al., "Camp-Specific Phosphodiesterase Inhibitor, Rolipram, Reduces Eosinophil Infiltration Evoked by Leukotrienes or by Histamine in Guinea Pig Conjunctiva", <i>Inflammation</i> , 17(1):25-31 (1993).
	*C14	Okai, et al., "Possible Immunomodulating Activities of Carotenoids in In Vitro Cell Culture Experiments", Int. J. Immunopharmac., 18(12):753-758 (1996).
	*C15	Saponara, et al., "Inhibition of cAMP-Phosphodiesterase by Biflavones of Ginkgo Biloba in Rat Adipose Tissue", <i>J. Nat. Prod.</i> , 61(11):1386-1387 (1998).
	*C16	Shaban, et al., "Phosphatidylglycerol Potently Protects Human Retinal Pigment Epithelial Cells Against Apoptosis Induced by A2E, a Compound Suspected to Cause Age-Related Macula Degeneration", <i>Exp. Eye Res.</i> , 75(1):99-108 (2002).
	*C17	Vint, et al., "The Gold Anti-Rheumatic Drug Auranofin Governs T Cell Activation by Enhancing Oxygen Free Radical Production", Eur. J. Immunol., 24(9):1961-1965 (1994).
	*C18	Vint, et al., "The Interaction of Auranofin and Buthionine Sulfoximine Blocks Activation of Human Peripheral T Lymphocytes", Cell. Immunol., 152(1):152-161 (1993).
	*C19	Vint, et al., "The Effects of Auranofin on Activation and Interleukin-2 Release from Human Peripheral Blood Mononuclear Cells", Agents and Actions, 40(3/4):209-214 (1993).
	*C20	Wang, et al., "Astaxanthin-Rich Algal Meal and Vitamin C Inhibit Helicobacter Pylori Infection in BALB/cA Mice", Antimicrobial Agents and Chemotherapy, 44(9):2452-2457 (2000).

^{*} a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior applications, Serial No.10/621,802, filed July 16, 2003, and Serial No. 10/345,856, filed January 16, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications)

	 	Y
Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4472559v.1